Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 136,500 shares, a drop of 23.3% from the March 31st total of 178,000 shares. Based on an average daily volume of 204,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 1.8% of the shares of the company are sold short.

Institutional Investors Weigh In On Mustang Bio

A hedge fund recently bought a new stake in Mustang Bio stock. Armistice Capital LLC purchased a new position in shares of Mustang Bio, Inc. (NASDAQ:MBIO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 435,764 shares of the company’s stock, valued at approximately $588,000. Armistice Capital LLC owned approximately 4.73% of Mustang Bio at the end of the most recent reporting period. Institutional investors own 9.95% of the company’s stock.

Mustang Bio Price Performance

Shares of Mustang Bio stock traded down $0.03 during midday trading on Friday, hitting $0.32. The company had a trading volume of 269,716 shares, compared to its average volume of 261,815. The business’s 50 day simple moving average is $0.92 and its two-hundred day simple moving average is $1.27. The stock has a market cap of $3.28 million, a PE ratio of -0.05 and a beta of 1.58. Mustang Bio has a 1-year low of $0.32 and a 1-year high of $8.17.

Mustang Bio (NASDAQ:MBIO) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.68) by $0.97. On average, sell-side analysts expect that Mustang Bio will post -3.25 EPS for the current fiscal year.

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.